Figure 3.
Figure 3. Characterization of aberrant Aα chain. (A) Immunoblot of plasma, after SDS-PAGE, with antibody to Aα241-476 before and after the addition of thrombin. Lanes 1 and 2, normal control; lanes 3 and 4, patient II.2. The patient lacks normal Aα chains, but fibrinopeptide A is successfully removed from the N-terminus of the defective chain by thrombin, suggesting C-terminal truncation. (B) Immunoblot of SDS-PAGE using antiserum to whole fibrinogen. Lane 1, normal plasma; lane 2, patient II.2; lane 3 homozygote for AαOtago truncation with a predicted mass of 30 862 Da.

Characterization of aberrant Aα chain. (A) Immunoblot of plasma, after SDS-PAGE, with antibody to Aα241-476 before and after the addition of thrombin. Lanes 1 and 2, normal control; lanes 3 and 4, patient II.2. The patient lacks normal Aα chains, but fibrinopeptide A is successfully removed from the N-terminus of the defective chain by thrombin, suggesting C-terminal truncation. (B) Immunoblot of SDS-PAGE using antiserum to whole fibrinogen. Lane 1, normal plasma; lane 2, patient II.2; lane 3 homozygote for AαOtago truncation with a predicted mass of 30 862 Da.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal